Select publications

Advani R et al. Stage I and II follicular non-Hodgkin’s lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 2004;22(8):1454-9. Abstract

Cheung MC et al. Rituximab for indolent lymphoma: An analysis of outcomes in a large population-wide study. Proc ASH 2003;Abstract 5754.

Dreyling MH et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASH 2003;Abstract 351.

Friedberg JW et al. Utilization of rituximab therapy in patients (pts) with newly diagnosed follicular (FL) and diffuse large B cell (DLCL) non-Hodgkin’s lymphoma (NHL) in the United States: An analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. Proc ASH 2003;Abstract 1800.

Giraldo P et al. Follow-up during four years after anti CD20 (Rituximab) trial in relapsed follicular lymphoma. Proc ASH 2003;Abstract 4933.

Hainsworth JD et al. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin’s lymphoma (NHL): Long-term follow-up of a Minnie Pearl Cancer Research Network Phase II Trial. Proc ASH 2003;Abstract 1496.

Hainsworth JD et al. Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin’s lymphoma (NHL) responding to singleagent rituximab: A randomized trial of the Minnie Pearl Cancer Research Network. Proc ASH 2003;Abstract 231.

Hiddemann W et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASH 2003;Abstract 352.

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004;Abstract 6502.

Horning SJ et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004;22(15):3032-8. Abstract

Lossos IS et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37. Abstract

Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins Lymphoma. Proc ASH 2003;Abstract 87.

Miller TP et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;339:21-6. Abstract

Neumann F et al. Maintenance therapy using the anti-CD20 antibody rituximab in patients with B-cell non-Hodgkin lymphoma. Proc ASH 2003;Abstract 4915.

Rambaldi A et al. Long term improvement of clinical outcome of follicular lymphoma patients achieving a molecular response after sequential CHOP and rituximab treatment: Predictive value of real time quantitative PCR to identify responding patients. Proc ASH 2003;Abstract 1487.